2-(2-(4-chlorophenyl)ethoxy)adenosine

a adenosine A2A receptor agonist

Also Known As:

MRE0094

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleosides: 360
        Adenosine: 12431
        2-(2-(4-chlorophenyl)ethoxy)adenosine: 2
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Purine Nucleosides: 360
    - Adenosine: 12431
      - 2-(2-(4-chlorophenyl)ethoxy)adenosine: 2
  - Ribonucleosides: 49
    - Adenosine: 12431
      - 2-(2-(4-chlorophenyl)ethoxy)adenosine: 2

Experts

1.	Jones, Rhys: 1 article (01/2010)
2.	Mantell, Simon: 1 article (01/2010)
3.	Trevethick, Mike: 1 article (01/2010)
4.	Cronstein, Bruce N: 1 article (02/2002)
5.	Desai, Avani: 1 article (02/2002)
6.	Montesinos, M Carmen: 1 article (02/2002)
7.	Victor-Vega, Cassandre: 1 article (02/2002)

Related Diseases

1.	Wounds and Injuries (Trauma) 02/01/2002 - "We found that application of MRE0094 (1 microg/wound and 10 microg/wound) and CGS-21680 (1 microg/wound and 5 microg/wound) achieved 50% wound closure significantly more rapidly than control application (day 1.9, 1.9, 3.5, 3.2, respectively, versus control day 4, p < 0.05 ANOVA). " 02/01/2002 - "To further confirm the efficacy of adenosine A2A receptor agonists as promoters of wound healing, we compared the effect of MRE0094, a novel selective adenosine A2A receptor agonist, to CGS-21680, a reference selective adenosine A2A receptor agonist, as well as to recombinant human platelet-derived growth factor (0.01% Becaplermin gel), an agent currently used to promote healing of diabetic ulcers, on wound closure in healthy BALB/C mice. "
2.	Ulcer 02/01/2002 - "To further confirm the efficacy of adenosine A2A receptor agonists as promoters of wound healing, we compared the effect of MRE0094, a novel selective adenosine A2A receptor agonist, to CGS-21680, a reference selective adenosine A2A receptor agonist, as well as to recombinant human platelet-derived growth factor (0.01% Becaplermin gel), an agent currently used to promote healing of diabetic ulcers, on wound closure in healthy BALB/C mice. "
3.	Allergic Rhinitis 01/01/2010 - "Adenosine A(2A) receptor agonists have been assessed as topical agents: GW328267X (GSK; allergic rhinitis and asthma), UK-432097 (Pfizer; chronic obstructive pulmonary disease [COPD]) and Sonedenoson (MRE0094, King Pharmaceuticals; wound healing). "
4.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2010 - "Adenosine A(2A) receptor agonists have been assessed as topical agents: GW328267X (GSK; allergic rhinitis and asthma), UK-432097 (Pfizer; chronic obstructive pulmonary disease [COPD]) and Sonedenoson (MRE0094, King Pharmaceuticals; wound healing). "
5.	Asthma (Bronchial Asthma) 01/01/2010 - "Adenosine A(2A) receptor agonists have been assessed as topical agents: GW328267X (GSK; allergic rhinitis and asthma), UK-432097 (Pfizer; chronic obstructive pulmonary disease [COPD]) and Sonedenoson (MRE0094, King Pharmaceuticals; wound healing). "

Related Drugs and Biologics

1.	Adenosine A2A Receptor (Adenosine A2A Receptors)
2.	Adenosine A2 Receptor Agonists
3.	Platelet-Derived Growth Factor
4.	Becaplermin (PDGF-BB)
5.	UK-432097